Figure 5.

Uptake of radiolabelled anti-VCAM-1 mAb into rat skin sites. Skin sites were un-injected, or injected intradermally with Tyrode solution, PAF, or LTB₄(both at 10⁻¹⁰ mol/site). At 1 or 4 hr post injections, the animals received an intravenous dose of radiolabelled antibodies including ¹²⁵I-labelled 5F10 (anti-VCAM-1) and ¹¹¹In-labelled control mAb. Five minutes later, the circulation was perfused and the skin sites removed and localisation of antibodies was quantified as described in the Materials and Methods. The graph shows the percentage uptake of the injected dose (ID) of radiolabelled 5F10 per gram of tissue, corrected for the non-specific uptake of radiolabelled control mAb (filled bars, n = 4 rats). Some animals received both the radiolabelled mAb and a 50-fold excess of unlabelled 5F10 (open bars, n = 3 rats). The results are mean±SEM for n number of rats. Asterisk indicates a significant difference from the uptake in uninjected sites, P < 0·05.